Potentials of ribosomopathy gene as pharmaceutical targets for cancer treatment
10.1016/j.jpha.2023.10.001
- Author:
Wang MENGXIN
1
,
2
;
Vulcano STEPHEN
;
Xu CHANGLU
;
Xie RENJIAN
;
Peng WEIJIE
;
Wang JIE
;
Liu QIAOJUN
;
Jia LEE
;
Li ZHI
;
Li YUMEI
Author Information
1. Key Laboratory of Biomaterials and Biofabrication in Tissue Engineering of Jiangxi Province,Gannan Medical University,Ganzhou,Jiangxi,341000,China
2. School of Rehabilitation Medicine,Gannan Medical University,Ganzhou,Jiangxi,341000,China
- Keywords:
Ribosome biogenesis;
Ribosomopathy gene;
Cancer treatment target;
Pharmaceutical target
- From:
Journal of Pharmaceutical Analysis
2024;14(3):308-320
- CountryChina
- Language:Chinese
-
Abstract:
Ribosomopathies encompass a spectrum of disorders arising from impaired ribosome biogenesis and reduced functionality.Mutation or dysexpression of the genes that disturb any finely regulated steps of ribosome biogenesis can result in different types of ribosomopathies in clinic,collectively known as ribosomopathy genes.Emerging data suggest that ribosomopathy patients exhibit a significantly heightened susceptibility to cancer.Abnormal ribosome biogenesis and dysregulation of some ribo-somopathy genes have also been found to be intimately associated with cancer development.The cor-relation between ribosome biogenesis or ribosomopathy and the development of malignancies has been well established.This work aims to review the recent advances in the research of ribosomopathy genes among human cancers and meanwhile,to excavate the potential role of these genes,which have not or rarely been reported in cancer,in the disease development across cancers.We plan to establish a theoretical framework between the ribosomopathy gene and cancer development,to further facilitate the potential of these genes as diagnostic biomarker as well as pharmaceutical targets for cancer treatment.
